If there was going to be a buyout it would have happened with Johnson & Johnson. They want Aragon for their prostate cancer drug that is not even approved yet. That just proves there is no interest in provenge. J & J could have bought DNDN with an approved prostate cancer drug but must have felt it isn't worth it. Lets face it, no one wants DNDN and provenge.
We don't need stuffy, traditional JNJ. They can't even avoid recalls for OTC pills let alone advanced medical therapy products. I thought JNJ at first- that they needed to add to Pca space. They chose the hard-wire telephone way to do that - oral medication. Who knows if Aragon's drug will improve survival or make it to market based on safety. We shall see. It is amazing the trust WS puts such faith in unproven vs proven therapies. All based on margins / profit, not value to patients.
Johnson & Johnson bought Aragon, They may have looked at DNDN and talk was in place with higher offers than Johnson & Johnson wanted to spend.
There also maybe ink on the papers already waiting for the EU approval. Provenge is not cheap to make or sell. This is one reason why this is a hard space to break into. We need a partner with a huge sales team and connections with the doctors and hospitals.
There will be a low bid first around 6 to 8. Then if there is no other bidder they will push hard then up the price to 8 to 10 and the deal will close. If other bidders pop up who know where we go. Big holders should be pushing for open bid on DNDN soon if JJ can't turn this ship. These numbers are gold now people! That's why BR and others are buying. Buy and walk away!